StockData
Cellectis S.A. logo

Cellectis S.A. (CLLS) stock

CLLSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 20, 2026Score 3/30
$1.03−0.03 (-2.83%)

Close on Nov 18, 2026Market cap $103.35MP/E –Yield –

Cellectis net income

Net income is the profit left for shareholders after every expense, interest and tax.

Cellectis's net income for the twelve months ending Dec 31, 2023 was -$101.06M. For fiscal 2025 it was -$67.59M. The highest annual figure on record is -$22.80M in fiscal 2015.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$67.59M–
FY2024Dec 31, 2024-$36.76M–
FY2023Dec 31, 2023-$101.06M–
FY2022Dec 31, 2022-$106.14M–
FY2021Dec 31, 2021-$114.20M–
FY2020Dec 31, 2020-$81.07M–
FY2019Dec 31, 2019-$102.09M–
FY2018Dec 31, 2018-$78.69M–
FY2017Dec 31, 2017-$99.37M–
FY2016Dec 31, 2016-$67.26M–
FY2015Dec 31, 2015-$22.80M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2025Jun 30, 2025-$23.74M–
Q2 FY2024Jun 30, 2024-$25.27M–
Q4 FY2023Dec 31, 2023-$41.80M–
Q3 FY2023Sep 30, 2023-$17.48M–
Q2 FY2023Jun 30, 2023-$11.71M–
Q2 FY2022Jun 30, 2022-$18.95M–
Q2 FY2021Jun 30, 2021-$39.92M–
Q2 FY2020Jun 30, 2020-$32.26M–
Q2 FY2019Jun 30, 2019-$33.45M–

More Cellectis figures

See a number that looks wrong?